Company Badge
USPTO Data Jan 1 1976 - Oct 13 2026
3 Patents
#1,199 in San Diego, CA
#16,858 in California
#73,860 in US
Ab Initio Biotherapeutics, Inc.
Forward Citations = 46
5 inventors:
San Diego, CA, United States of America
Ab Initio Biotherapeutics, Inc.
EPO Patents = 1
Forward Citations = 46
Loading Chart...
Loading Chart...
5 inventors (with patents filed for the assignee):
Roy Louis Maute (3 out of 10 patents)
Andrew Curtis Kruse (3 out of 11 patents)
Aashish Manglik (3 out of 16 patents)
4. Kenneth S Lin (3 out of 3 patents)
5. Aaron Michael Ring (3 out of 35 patents)
3 patents:
Company Overview
Ab Initio Biotherapeutics, Inc. is a biotechnology company that specializes in the discovery and development of novel antibody-based therapeutics. Leveraging their proprietary technology platform, Ab Initio is dedicated to advancing innovative solutions for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. With a focus on precision medicine and personalized treatment approaches, the company is committed to making a meaningful impact on patient care.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ab Initio Biotherapeutics, Inc.. Retrieved from https://idiyas.com/company/ab-initio-biotherapeutics
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]